Reduced-Intensity Conditioning Followed by Related Allografts in Hematologic Malignancies: Long-Term Outcomes Most Successful in Indolent and Aggressive.

Slides:

Advertisements

Similar presentations

Comparable results of umbilical cord blood and HLA-matched sibling donor hematopoietic stem cell transplantation after reduced-intensity preparative regimen.

Advertisements

Navneet S. Majhail, Todd DeFor, Hillard M. Lazarus, Linda J. Burns

Promising Progression-Free Survival for Patients Low and Intermediate Grade Lymphoid Malignancies after Nonmyeloablative Umbilical Cord Blood Transplantation

Follistatin and Endoglin: Potential Biomarkers of Endothelial Damage and Non-Relapse Mortality after Myeloablative Allogeneic Hematopoietic Cell Transplantation.

Successful Remission Rates and Survival after Lymphodepleting Chemotherapy and Donor Lymphocyte Infusion for Relapsed Hematologic Malignancies Postallogeneic.

Monosomal Karyotype at the Time of Diagnosis or Transplantation Predicts Outcomes of Allogeneic Hematopoietic Cell Transplantation in Myelodysplastic.

Loss of T Follicular Helper Cells in the Peripheral Blood of Patients with Chronic Graft- versus-Host Disease David A. Knorr, Hongbo Wang, Mukta Aurora,

Does the Hematopoietic Cell Transplantation Specific Comorbidity Index Predict Transplant Outcomes? A Validation Study in a Large Cohort of Umbilical.

Long-Term Outcomes of Autologous Stem Cell Transplantation for Follicular Non- Hodgkin Lymphoma: Effect of Histological Grade and Follicular International.

FDG-PET Interpreted By Deauville Criteria Prior to Allogeneic Transplantation Predicts Outcomes in Patients with Relapsed or Refractory Hodgkin Lymphoma

Peter Hurley, Suma Konety, Qing Cao, Daniel Weisdorf, Anne Blaes

Changing Trends of Unrelated Umbilical Cord Blood Transplantation for Hematologic Diseases in Patients Older than Fifty Years: A Eurocord-Center for International.

Autologous versus Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Patients with Chemosensitive Follicular Non-Hodgkin Lymphoma beyond.

Survival Differences between Adolescents/Young Adults and Children with B Precursor Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Cell Transplantation

Impact of Allele-Level HLA Mismatch on Outcomes in Recipients of Double Umbilical Cord Blood Transplantation Claudio G. Brunstein, Effie W. Petersdorf,

Navneet S. Majhail, Todd DeFor, Hillard M. Lazarus, Linda J. Burns

Late Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation Aazim K. Omer, Daniel J. Weisdorf, Aleksandr Lazaryan,

Long-Term Results of Autologous Stem Cell Transplantation for Primary Refractory or Relapsed Hodgkin’s Lymphoma Navneet S. Majhail, Daniel J. Weisdorf,

Assessment of the Hematopoietic Cell Transplantation Comorbidity Index in Non- Hodgkin Lymphoma Patients Receiving Reduced-Intensity Allogeneic Hematopoietic.

Alternate Donor Hematopoietic Cell Transplantation (HCT) in Non-Hodgkin Lymphoma Using Lower Intensity Conditioning: A Report from the CIBMTR Gregory.

Delayed immune reconstitution after allogeneic transplantation increases the risks of mortality and chronic GVHD by Nelli Bejanyan, Claudio G. Brunstein,

T Cell–Replete Peripheral Blood Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide Results in Outcomes Similar.

Myeloablative, but not Reduced-Intensity, Conditioning Overcomes the Negative Effect of Flow-Cytometric Evidence of Leukemia in Acute Myeloid Leukemia

Cytomegalovirus Infection after Allogeneic Transplantation: Comparison of Cord Blood with Peripheral Blood and Marrow Graft Sources Christopher M. Walker,

Jill C. Beck, John E. Wagner, Todd E. DeFor, Claudio G

Monosomal Karyotype Provides Better Prognostic Prediction after Allogeneic Stem Cell Transplantation in Patients with Acute Myelogenous Leukemia Betul.

Claudio G. Brunstein, Bruce R. Blazar, Jeffrey S

Higher Dose of Mycophenolate Mofetil Reduces Acute Graft-versus-Host Disease in Reduced-Intensity Conditioning Double Umbilical Cord Blood Transplantation

Similar Overall Survival Using Sibling, Unrelated Donor, and Cord Blood Grafts after Reduced-Intensity Conditioning for Older Patients with Acute Myelogenous.

Claudio Brunstein, MD, PhD, Keli Hippen, Todd E

Outcome of Lower-Intensity Allogeneic Transplantation in Non-Hodgkin Lymphoma after Autologous Transplantation Failure César O. Freytes, Mei-Jie Zhang,

Unrelated Cord Blood Transplantation in Adult and Pediatric Acute Lymphoblastic Leukemia: Effect of Minimal Residual Disease on Relapse and Survival

The International Prognostic Index Assessed at Relapse Predicts Outcomes of Autologous Transplantation for Diffuse Large-Cell Non-Hodgkin’s Lymphoma in.

Improvement of Pulmonary Function with Imatinib Mesylate in Bronchiolitis Obliterans Following Allogeneic Hematopoietic Cell Transplantation Navneet.

A Randomized Trial of One versus Two Doses of Influenza Vaccine after Allogeneic Transplantation Nicole A. Karras, Matthew Weeres, Wendy Sessions, Xiyan.

Decreased Infections in Recipients of Unrelated Donor Hematopoietic Cell Transplantation from Donors with an Activating KIR Genotype Marcie Tomblyn,

Relapse of Lymphoma after Allogeneic Hematopoietic Cell Transplantation: Management Strategies and Outcome Kitsada Wudhikarn, Claudio G. Brunstein, Veronika.

Hematopoietic Cell Transplantation for Acute Leukemia and Advanced Myelodysplastic Syndrome in Fanconi Anemia Richard Mitchell, Todd Defor, John E. Wagner,

Association between Genetic Variants in the Base Excision Repair Pathway and Outcomes after Hematopoietic Cell Transplantations Bharat Thyagarajan, Bruce.

Effect of Conditioning Regimen Intensity on Acute Myeloid Leukemia Outcomes after Umbilical Cord Blood Transplantation Betul Oran, John E. Wagner, Todd.

Allogeneic Hematopoietic Stem Cell Transplantation in Adult Acute Lymphocytic Leukemia: Impact of Donor Source on Survival Priya Kumar, Todd E. Defor,

Adjusting Cyclophosphamide Dose in Obese Patients with Lymphoma Is Safe and Yields Favorable Outcomes after Autologous Hematopoietic Cell Transplantation

Favorable Overall Survival with Fully Myeloablative Allogeneic Stem Cell Transplantation for Follicular Lymphoma John Kuruvilla, Gregory Pond, Richard.

Allogeneic Hematopoietic Cell Transplantation in Children with Relapsed Acute Lymphoblastic Leukemia Isolated to the Central Nervous System Paul D. Harker-Murray,

An Exploratory Analysis of Mitochondrial Haplotypes and Allogeneic Hematopoietic Cell Transplantation Outcomes Julie A. Ross, Jakub Tolar, Logan G. Spector,

Hematopoietic Cell Transplantation for Children with Acute Lymphoblastic Leukemia in Second Complete Remission: Similar Outcomes in Recipients of Unrelated.

Adaptive Natural Killer Cell and Killer Cell Immunoglobulin–Like Receptor–Expressing T Cell Responses are Induced by Cytomegalovirus and Are Associated.

Outcomes of Cord Blood Transplantation as Salvage Therapy after Graft Failure or Relapse after Prior Allogeneic Transplantation Rachel B. Salit, Filippo.

Regression Models for Hazard Rates Versus Cumulative Incidence Probabilities in Hematopoietic Cell Transplantation Data Brent R. Logan, Mei-Jie Zhang,

Robin L. Williams, Sarah Cooley, Veronika Bachanova, Bruce R

Recipient HLA-C Haplotypes and microRNA 148a/b Binding Sites Have No Impact on Allogeneic Hematopoietic Cell Transplantation Outcomes Gretchen A. Hoff,

Chronic Graft-Versus-Host Disease (cGVHD) following Unrelated Donor Hematopoietic Stem Cell Transplantation (HSCT): Higher Response Rate In Recipients.

Richard Mitchell, John E. Wagner, Claudio Brunstein, Qing Cao, David H

Richard Mitchell, John E. Wagner, Claudio G

Reduced-Intensity Allogeneic Transplant in Patients Older Than 55 Years: Unrelated Umbilical Cord Blood Is Safe and Effective for Patients without a Matched.

Umbilical Cord Blood Transplantation Outcomes in Acute Myelogenous Leukemia/Myelodysplastic Syndrome Patients Aged ≥70 Years Karamjeet S. Sandhu, Claudio.

A Refined Risk Score for Acute Graft-versus-Host Disease that Predicts Response to Initial Therapy, Survival, and Transplant-Related Mortality Margaret.

Blood and Marrow Transplant Handbook

Comparable Outcomes after HLA-Matched Sibling and Alternative Donor Hematopoietic Cell Transplantation for Children with Fanconi Anemia and Severe Aplastic.

Comorbidities, Not Age, Impact Outcomes in Autologous Stem Cell Transplant for Relapsed Non-Hodgkin Lymphoma Tanya M. Wildes, Kristan M. Augustin, Diane.

Reduced Intensity Versus Myeloablative Conditioning Allogeneic HCT for Relapsed/Refractory Lymphoma: Applying Refined Disease Risk Index (DRI) to Improve.

Extramedullary Relapse of Acute Myelogenous Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: Better Prognosis Than Systemic Relapse

Reduced Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation: Current Perspectives Brenda M. Sandmaier, Stephen Mackinnon, Richard.

Clinical Outcome following Autologous and Allogeneic Blood and Marrow Transplantation for Relapsed Diffuse Large-Cell Non-Hodgkin’s Lymphoma Ivan Aksentijevich,

Matching at Human Leukocyte Antigen-C Improved the Outcomes after Double Umbilical Cord Blood Transplantation for Recipients of Two to Four of Six Human.

Futility of Relapsed Diffuse Large B Cell Lymphoma Transplantation?

Long-Term Results Of Autologous Hematopoietic Cell Transplantation For Peripheral T Cell Lymphoma: The Stanford Experience Andy I. Chen, Alex McMillan,

Promising Progression Free and Overall Survival Using a Novel (CY/FLU/TBI) Reduced-Intensity Conditioning (RIC) Regimen for Allogeneic Sibling Stem Cell.

Claudio G. Brunstein, David H. McKenna, Todd E

Sirolimus and Mycophenolate Mofetil as Calcineurin Inhibitor–Free Graft-versus-Host Disease Prophylaxis for Reduced-Intensity Conditioning Umbilical Cord.

Presentation transcript:

Reduced-Intensity Conditioning Followed by Related Allografts in Hematologic Malignancies: Long-Term Outcomes Most Successful in Indolent and Aggressive Non- Hodgkin Lymphomas Erica D. Warlick, Marcie Tomblyn, Qing Cao, Todd DeFor, Bruce R. Blazar, Margaret MacMillan, Michael Verneris, John Wagner, Kathryn Dusenbery, Mukta Aurora, Veronika Bachanova, Claudio Brunstein, Linda Burns, Sarah Cooley, Dan Kaufman, Navneet S. Majhail, Brian McClune, Philip McGlave, Jeffrey Miller, Betul Oran, Arne Slungaard, Gregory Vercellotti, Daniel J. Weisdorf Biology of Blood and Marrow Transplantation Volume 17, Issue 7, Pages 1025-1032 (July 2011) DOI: 10.1016/j.bbmt.2010.10.030 Copyright © 2011 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 Four-year OS by disease group. Biology of Blood and Marrow Transplantation 2011 17, 1025-1032DOI: (10.1016/j.bbmt.2010.10.030) Copyright © 2011 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 2 Four-year incidence of relapse by disease group. Biology of Blood and Marrow Transplantation 2011 17, 1025-1032DOI: (10.1016/j.bbmt.2010.10.030) Copyright © 2011 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 3 One-year TRM by comorbidity score. Biology of Blood and Marrow Transplantation 2011 17, 1025-1032DOI: (10.1016/j.bbmt.2010.10.030) Copyright © 2011 American Society for Blood and Marrow Transplantation Terms and Conditions